IN2014CN00675A - - Google Patents

Info

Publication number
IN2014CN00675A
IN2014CN00675A IN675CHN2014A IN2014CN00675A IN 2014CN00675 A IN2014CN00675 A IN 2014CN00675A IN 675CHN2014 A IN675CHN2014 A IN 675CHN2014A IN 2014CN00675 A IN2014CN00675 A IN 2014CN00675A
Authority
IN
India
Prior art keywords
methods
tissue
perform
signaling pathway
cellular signaling
Prior art date
Application number
Other languages
English (en)
Inventor
Wilhelmus Franciscus Johannes Verhaegh
Stolpe Anja Van De
Hendrik Jan Van Ooijen
Kalyana Chakravarthi Dulla
De Inda Marcia Alves
Ralf Hoffmann
Original Assignee
Koninkl Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Nv filed Critical Koninkl Philips Nv
Publication of IN2014CN00675A publication Critical patent/IN2014CN00675A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/04—Inference or reasoning models
    • G06N5/048—Fuzzy inferencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Pathology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
IN675CHN2014 2011-07-19 2012-07-19 IN2014CN00675A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509137P 2011-07-19 2011-07-19
EP11178148A EP2549399A1 (de) 2011-07-19 2011-08-19 Beurteilung der Wnt-Weg-Aktivität mit probabilistischer Modellierung der Zielgenexpression
PCT/IB2012/053686 WO2013011479A2 (en) 2011-07-19 2012-07-19 Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression

Publications (1)

Publication Number Publication Date
IN2014CN00675A true IN2014CN00675A (de) 2015-04-03

Family

ID=44582424

Family Applications (1)

Application Number Title Priority Date Filing Date
IN675CHN2014 IN2014CN00675A (de) 2011-07-19 2012-07-19

Country Status (12)

Country Link
US (2) US11443831B2 (de)
EP (6) EP2549399A1 (de)
JP (3) JP6204354B2 (de)
KR (1) KR102064004B1 (de)
CN (2) CN103649337B (de)
BR (1) BR112014000965B8 (de)
DK (3) DK3173489T3 (de)
ES (3) ES2617195T3 (de)
IN (1) IN2014CN00675A (de)
MX (1) MX352827B (de)
RU (1) RU2719194C2 (de)
WO (1) WO2013011479A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2549399A1 (de) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Beurteilung der Wnt-Weg-Aktivität mit probabilistischer Modellierung der Zielgenexpression
ES2968742T3 (es) 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
AU2013368945B2 (en) 2012-12-26 2020-01-23 Innosign B.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
EP3372695B1 (de) 2013-04-26 2020-09-09 Koninklijke Philips N.V. Medizinische prognose und vorhersage der behandlungsreaktion mithilfe mehrfacher zellsignalwegaktivitäten
CN105706097A (zh) * 2013-06-28 2016-06-22 南托米克斯有限责任公司 用于诊断检测的识别的途径分析
WO2015049688A2 (en) 2013-10-02 2015-04-09 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
AU2014375206B2 (en) 2014-01-03 2021-09-30 Innosign B.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
US9810762B2 (en) * 2014-09-11 2017-11-07 Google Inc. Calculating mean wireless signal strengths using a gaussian process approach incorporating predictive standard deviations
US9880257B2 (en) * 2014-09-11 2018-01-30 Google Llc Gaussian process-based approach for identifying correlation between wireless signals
US9838847B2 (en) 2014-09-11 2017-12-05 Google LLP Data driven evaluation and rejection of trained Gaussian process-based wireless mean and standard deviation models
WO2016042164A1 (en) * 2014-09-19 2016-03-24 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Unidv. Trinity Of Queen Elizabeth, Near Dublin A method of predicting risk of recurrence of cancer
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
JP6415712B2 (ja) * 2014-10-24 2018-10-31 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 標的遺伝子発現の数学的モデル化を用いるＴＧＦ−β細胞シグナル伝達経路活性の評価
CN108064311B (zh) 2014-10-24 2022-10-28 皇家飞利浦有限公司 使用多种细胞信号传导途径活性的治疗反应的医学预后和预测
EP3210144B1 (de) * 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medizinische prognose und vorhersage der behandlungsreaktion mithilfe der aktivitäten mehrerer zellsignalisierungspfade
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
WO2017029215A1 (en) * 2015-08-14 2017-02-23 Koninklijke Philips N.V. Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
CN108292326B (zh) * 2015-08-27 2022-04-01 皇家飞利浦有限公司 用于识别功能性患者特异性体细胞畸变的整合方法和系统
CN106897578B (zh) * 2015-12-15 2020-02-14 中国科学院大连化学物理研究所 一种细胞基因翻译过程建模方法
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
US20170329914A1 (en) * 2016-05-11 2017-11-16 International Business Machines Corporation Predicting Personalized Cancer Metastasis Routes, Biological Mediators of Metastasis and Metastasis Blocking Therapies
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10621236B2 (en) * 2016-09-16 2020-04-14 At&T Intellectual Property I, L.P. Concept based querying of graph databases
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018089927A1 (en) * 2016-11-11 2018-05-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of instance-specific somatic genome alterations with functional impact
US20190376142A1 (en) 2016-11-25 2019-12-12 Koninklijke Philips N.V. Method to distinguish tumor supressive foxo activity from oxidative stress
CN106755464A (zh) * 2017-01-11 2017-05-31 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107184991B (zh) * 2017-05-03 2020-05-26 武汉爱博泰克生物科技有限公司 PRDM15基因序列在制备NF-κB抑制剂中的应用
CN107164508A (zh) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
EP3431582A1 (de) 2017-07-18 2019-01-23 Koninklijke Philips N.V. Zellkulturmaterialen
CN107201411A (zh) * 2017-07-27 2017-09-26 上海市长宁区妇幼保健院 Mylk基因作为诊断子宫内膜癌的标志物
CN107385051A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法
EP3462348A1 (de) * 2017-09-28 2019-04-03 Koninklijke Philips N.V. Bayessche inferenz
EP3461915A1 (de) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3692170A1 (de) 2017-10-02 2020-08-12 Koninklijke Philips N.V. Bestimmung des funktionellen zustands von immunzelltypen und immunreaktion
EP3462349A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären notch-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3461916A1 (de) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären jak-stat3-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3727351A4 (de) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center Manipulierte extrazelluläre vesikel für verbesserte freisetzung in gewebe
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
US11475995B2 (en) * 2018-05-07 2022-10-18 Perthera, Inc. Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking
CN113626397A (zh) * 2018-06-16 2021-11-09 王梅 对数据文件进行动态处理的方法及系统
US11354591B2 (en) 2018-10-11 2022-06-07 International Business Machines Corporation Identifying gene signatures and corresponding biological pathways based on an automatically curated genomic database
US20220076785A1 (en) * 2018-12-21 2022-03-10 Phil Rivers Technology, Ltd. Method for acquiring intracellular deterministic event, electronic device and storage medium
CN113785075A (zh) 2019-05-03 2021-12-10 皇家飞利浦有限公司 高级别浆液性卵巢癌的预后方法
EP3812474A1 (de) 2019-10-22 2021-04-28 Koninklijke Philips N.V. Verfahren zur prognose bei hochgradig serösem ovarialkrebs
JP2022532161A (ja) * 2019-05-08 2022-07-13 シーダーズ―シナイ メディカル センター 治療活性細胞およびエクソソーム
EP3739588A1 (de) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Beurteilung des aktivitäts-scores mehrerer signalisiserungspfade in atemwegsepithelzellen zur vorhersage der atemwegsepithelanomalität und des atemwegskrebsrisikos
US11367508B2 (en) 2019-08-16 2022-06-21 Tempus Labs, Inc. Systems and methods for detecting cellular pathway dysregulation in cancer specimens
EP3822368A1 (de) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Beurteilung der zellulären pr-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3835433A1 (de) 2019-12-12 2021-06-16 Koninklijke Philips N.V. Notch-signalweg-aktivität als prognostischer marker bei blasenkrebs
CA3163492A1 (en) * 2019-12-12 2021-06-17 Tempus Labs, Inc. Real-world evidence of diagnostic testing and treatment patterns in u.s. breast cancer patients
CN111139300B (zh) * 2020-02-19 2021-08-17 伯克利南京医学研究有限责任公司 一组结肠癌预后相关基因的应用
EP3882363A1 (de) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognosewege für sepsispatienten mit hohem risiko
EP4136261A1 (de) 2020-04-16 2023-02-22 InnoSIGN B.V. Prognostische wege für virusinfektionen
EP3978628A1 (de) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostische pfade für virusinfektionen
CN111739586B (zh) * 2020-06-17 2024-04-05 浙江大学 以87个基因作为生物标志物预测细胞增殖活性的模型
EP3940704A1 (de) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Verfahren zur bestimmung des differenzierungszustands einer stammzelle
EP3960875A1 (de) 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr-verfahren und kit zur bestimmung der pfadaktivität
EP3965119A1 (de) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Verfahren zur schätzung der heterogenität eines tumors basierend auf werten für zwei oder mehr genommutationen und/oder genexpressionsbezogene parameter sowie entsprechende vorrichtungen
EP3974540A1 (de) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Verfahren zur vorhersage einer immuntherapieresistenz
EP4015651A1 (de) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Behandlungsvorhersage und wirksamkeit einer anti-tnf-alpha-behandlung bei ibd-patienten
EP4039825A1 (de) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Vergleich und standardisierung von zell- und gewebekultur
JP2024514404A (ja) 2021-03-11 2024-04-02 コーニンクレッカ フィリップス エヌ ヴェ 高リスク敗血症患者のための予後経路
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
WO2023084039A1 (en) * 2021-11-15 2023-05-19 Innosign B.V. Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
WO2024033063A1 (en) 2022-08-12 2024-02-15 Innosign B.V. Prediction and monitoring of immunotherapy in cancer
CN116083590B (zh) * 2023-03-23 2024-03-22 雄安妙心医学检验有限公司 一种基因检测试剂盒及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
EP1380644A1 (de) 2002-07-08 2004-01-14 Kylix B.V. Verwendung spezifischer TCF Zielgene zur Identifizierung von Medikamenten zur Behandlung von Krebsarten, insbesondere Colorectalkrebs, bei denen TCF/beta-catenin/WNT Signaltransduktion eine zentrale Rolle spielt
WO2004022575A2 (en) 2002-09-05 2004-03-18 Toolgen, Inc. Bioinformatics analysis of cellular effects of artificial transcription factors
JP2008528975A (ja) * 2005-01-24 2008-07-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 細胞シグナル伝達系のモデリングのためのベイジアンネットワークの使用
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2007056344A2 (en) 2005-11-07 2007-05-18 Scanscout, Inc. Techiques for model optimization for statistical pattern recognition
EP2027549A2 (de) 2006-05-17 2009-02-25 The Trustees Of Boston University Verfahren zur bestimmung von transkriptionalen regelungswegen in organismen
WO2008086182A2 (en) * 2007-01-04 2008-07-17 University Of Rochester Use of gene signatures to design novel cancer treatment regimens
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
US20120252689A1 (en) 2011-04-01 2012-10-04 Zhong Wu Gene expression signature for wnt/b-catenin signaling pathway and use thereof
WO2012149609A1 (en) 2011-05-05 2012-11-08 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
EP2549399A1 (de) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Beurteilung der Wnt-Weg-Aktivität mit probabilistischer Modellierung der Zielgenexpression

Also Published As

Publication number Publication date
EP2549399A1 (de) 2013-01-23
EP3418396A1 (de) 2018-12-26
MX2014000557A (es) 2014-05-01
EP4130291B1 (de) 2024-01-10
WO2013011479A3 (en) 2013-03-14
JP2019129850A (ja) 2019-08-08
CN103649337B (zh) 2018-11-13
US11443831B2 (en) 2022-09-13
ES2874452T3 (es) 2021-11-05
EP4130291C0 (de) 2024-01-10
DK2734643T3 (en) 2017-03-20
EP3173489B1 (de) 2018-09-19
US20230105263A1 (en) 2023-04-06
EP2734643A2 (de) 2014-05-28
KR102064004B1 (ko) 2020-01-08
JP6204354B2 (ja) 2017-09-27
WO2013011479A2 (en) 2013-01-24
ES2700617T3 (es) 2019-02-18
BR112014000965A2 (pt) 2017-06-13
RU2014106026A (ru) 2015-08-27
KR20140046464A (ko) 2014-04-18
RU2719194C2 (ru) 2020-04-17
MX352827B (es) 2017-12-11
EP3831957A1 (de) 2021-06-09
US20140156200A1 (en) 2014-06-05
EP3831957B1 (de) 2022-09-07
DK3173489T3 (en) 2018-12-10
CN109852671A (zh) 2019-06-07
ES2617195T3 (es) 2017-06-15
EP3418396B1 (de) 2021-03-24
BR112014000965B1 (pt) 2021-08-24
JP6807430B2 (ja) 2021-01-06
BR112014000965B8 (pt) 2022-11-08
JP2017205129A (ja) 2017-11-24
EP4130291A1 (de) 2023-02-08
DK3418396T3 (da) 2021-05-25
JP2014520566A (ja) 2014-08-25
EP3173489A1 (de) 2017-05-31
EP2734643B1 (de) 2016-12-07
CN103649337A (zh) 2014-03-19
JP6783729B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
IN2014CN00675A (de)
MX2015008177A (es) Evaluacion de la actividad de la via de señalizacion celular utilizando combinacion(es) lineal(es) de expresiones de genes objetivo.
EP4349248A3 (de) Vorrichtung zur bestimmung von geschädigtem gewebe mit subepidermaler feuchtigkeitsmessung
GB2569921A (en) Bisymmetric comparison of sub-epidermal moisture values
PH12014501844B1 (en) Peptidomimetic macrocycles
EA201691368A1 (ru) ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ
MX2013004061A (es) Analogos de ciclosporina.
MX355543B (es) Macrociclos peptidomiméticos.
IT1407125B1 (it) Apparato e metodo per il monitoraggio del rischio di insorgenza della sindrome della morte in culla (sids) e della plagiocefalia posizionale.
PH12016500768A1 (en) Methods of treating and preventing graft versus host disease
EP2740073A4 (de) Verfahren und vorrichtung zur beurteilung der aktivität eines organs und verwendungen davon
MX2014004320A (es) Metodo y aparato para tratar a un paciente, ocluyendo intencionalmente un vaso sanguineo, que incluye un metodo y un aparato para inducir la perdida de peso en un paciente ocluyendo intencionalmente la arteria celiaca.
MX2016016756A (es) Terapia con células madre en patologías endometriales.
GB201217673D0 (en) Methods and apparatus for correcting for medical imaging data
MX2013004062A (es) Analogos de ciclosporina.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
SG196722A1 (en) Thawing vessel for biological products
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
UA111344C2 (uk) Спосіб діагностики сполучної тканини та його застосування
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
MX2020005037A (es) Métodos y sistemas para planteamientos de continuidad sinérgica para el tratamiento y conservación de células biológicas.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
EP3019186A4 (de) Verfahren zur gewinnung, lagerung und speicherung von proteinen aus einer feto-plazentalen einheit eines säugetiers sowie verwendung solcher proteine in zusammensetzungen und medizinischen behandlungen
WO2016107874A3 (en) Prenylcysteine oxidase 1 inhibitors for the prevention and/or treatment of oxidative stress-related degenerative diseases and prenylcysteine oxidase 1 as diagnostic marker
RU2012144141A (ru) Способ оценки вероятности возникновенения переломов при остеопорозе у женщин